Is TRSBF or RYLD a better dividend investment in 2026?

TRSBF currently yields 1.22% with a 5% 5-year dividend growth rate. RYLD yields 12.39% with 5% growth. The better choice depends on your goal: RYLD offers higher current income.

What is the dividend yield difference between TRSBF and RYLD?

TRSBF has a forward dividend yield of 1.22% ($0.03/share annually). RYLD yields 12.39% ($1.81/share annually). The yield gap is 11.17 percentage points.

Home › Compare › TRSBF vs RYLD

TRSBF vs RYLD: Dividend Comparison 2026

TRSBF yields 1.22% · RYLD yields 12.39%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 TRSBF wins by $9.04M in total portfolio value· pulled ahead in Year 5

INVESTMENT

TIME HORIZON10 years

TRSBF

● Live price

1.22%

Share price

$2.61

Annual div

$0.03

5Y div CAGR

100%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$9.08M

Annual income

$7,845,769.56

Full TRSBF calculator →

RYLD

● Live price

12.39%

Share price

$14.64

Annual div

$1.81

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$45.3K

Annual income

$2,682.98

Full RYLD calculator →

Portfolio growth — TRSBF vs RYLD

📍 TRSBF pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	TRSBF	RYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, TRSBF + RYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

TRSBF pays

RYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRSBF

Annual income on $10K today (after 15% tax)

$103.69/yr

After 10yr DRIP, annual income (after tax)

$6,668,904.13/yr

RYLD

Annual income on $10K today (after 15% tax)

$1,053.44/yr

After 10yr DRIP, annual income (after tax)

$2,280.53/yr

At 15% tax rate, TRSBF beats the other by $6,666,623.59/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRSBF + RYLD for your $10,000?

TRSBF: 50%RYLD: 50%

100% RYLD50/50100% TRSBF

Portfolio after 10yr

$4.56M

Annual income

$3,924,226.27/yr

Blended yield

86.00%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRSBF buys

RYLD buys

No recent congressional trades found for TRSBF or RYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricTRSBFRYLD

Forward yield	1.22%	12.39% ✓
Annual dividend / share	$0.03	$1.81 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	100% ✓	0%
Portfolio after 10y	$9.08M	$45.3K ✓
Annual income after 10y	$7,845,769.56 ✓	$2,682.98
Total dividends collected	$8.96M	$19.4K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: TRSBF vs RYLD ($10,000, DRIP)

Year	TRSBF Portfolio	TRSBF Income/yr	RYLD Portfolio	RYLD Income/yr	Gap
1	$10,944	$243.97	$11,939	$1,239.34	$995.00 → RYLD
2	$12,209	$499.06	$14,158	$1,382.89	$1.9K → RYLD
3	$14,104	$1,040.65	$16,682	$1,532.59	$2.6K → RYLD
4	$17,339	$2,247.09	$19,537	$1,687.64	$2.2K → RYLD
5← crossover	$23,716	$5,163.36	$22,752	$1,847.20	+$964.00 → TRSBF
6	$38,577	$13,200.74	$26,355	$2,010.43	+$12.2K → TRSBF
7	$81,413	$40,135.71	$30,376	$2,176.45	+$51.0K → TRSBF
8	$245,435	$158,323.22	$34,847	$2,344.43	+$210.6K → TRSBF
9	$1,154,758	$892,143.08	$39,800	$2,513.54	+$1.11M → TRSBF
10	$9,081,361	$7,845,769.56	$45,269	$2,682.98	+$9.04M → TRSBF

TRSBF vs RYLD: Complete Analysis 2026

TRSBF — Stock

3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, it offers Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections; and Inleusin, a human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up. Further, the company provides trading, project management and consultation, technology, and agricultural services. It has collaboration agreements with companies, such as AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and DanaFarber Cancer Institute. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.

Full TRSBF Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →

📬

Get this TRSBF vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRSBF vs SCHD TRSBF vs JEPI TRSBF vs O TRSBF vs KO TRSBF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.